TimesSquare Capital Management LLC Invests $15.90 Million in Tarsus Pharmaceuticals, Inc. $TARS

TimesSquare Capital Management LLC purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 267,505 shares of the company’s stock, valued at approximately $15,898,000. TimesSquare Capital Management LLC owned approximately 0.63% of Tarsus Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Norges Bank bought a new stake in Tarsus Pharmaceuticals during the 2nd quarter valued at about $19,095,000. MPM Bioimpact LLC purchased a new stake in shares of Tarsus Pharmaceuticals during the second quarter valued at approximately $13,834,000. Assenagon Asset Management S.A. grew its holdings in shares of Tarsus Pharmaceuticals by 25.1% during the third quarter. Assenagon Asset Management S.A. now owns 1,247,954 shares of the company’s stock valued at $74,166,000 after buying an additional 250,367 shares during the last quarter. Capricorn Fund Managers Ltd bought a new stake in shares of Tarsus Pharmaceuticals during the third quarter valued at approximately $14,264,000. Finally, Qube Research & Technologies Ltd raised its holdings in Tarsus Pharmaceuticals by 86.1% in the 2nd quarter. Qube Research & Technologies Ltd now owns 459,436 shares of the company’s stock worth $18,612,000 after acquiring an additional 212,592 shares during the last quarter. Institutional investors own 90.01% of the company’s stock.

Analyst Ratings Changes

TARS has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Guggenheim increased their price objective on Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Mizuho assumed coverage on Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price for the company. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. Finally, HC Wainwright lifted their price target on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a research note on Monday, October 20th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $82.29.

Insiders Place Their Bets

In related news, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the transaction, the chief executive officer directly owned 857,991 shares in the company, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dianne C. Whitfield sold 7,397 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total value of $592,499.70. Following the sale, the insider directly owned 38,958 shares of the company’s stock, valued at $3,120,535.80. This represents a 15.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 8.97% of the company’s stock.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS opened at $60.78 on Monday. The company has a quick ratio of 4.25, a current ratio of 4.29 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $2.58 billion, a PE ratio of -30.09, a price-to-earnings-growth ratio of 0.88 and a beta of 0.57. The firm’s 50 day moving average price is $74.28 and its 200-day moving average price is $67.20. Tarsus Pharmaceuticals, Inc. has a twelve month low of $38.51 and a twelve month high of $85.25.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.